Stoke Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.91M, a 245.31% increase year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $3.21M, a 219.22% increase year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.49M, a 1689.93% increase year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $554.00K, a 27.68% decline year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $8.60M, a 399.59% increase from fiscal 2024.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.72M, a 364.15% increase from fiscal 2023.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $371.00K, a 24.90% decline from fiscal 2022.
- Stoke Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $494.00K, a 36.42% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.91M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $3.21M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $8.60M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $2.49M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $554.00K 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $1.00M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $1.72M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $139.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $766.00K 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $250.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $371.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $161.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $48.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $158.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $494.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $33.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $326.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $93.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $777.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $73.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $161.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $371.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $2.84M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $682.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $368.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $199.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $314.00K 10-K · filed 2021-03-09 | |
| 2019-09-30 | $20.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $27.00K 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $74.00K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $19.00K 10-K · filed 2020-03-23 | |
| 2018-09-30 | $7.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $8.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |